ArticlePakistan journal of medical sciences2025
Genomic landscape of pathogenic mutations in Pakistani population with late-stage colorectal cancer.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Is p53 Immunohistochemistry a Reliable Indicator ofPakistan journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess the frequencies of pathogenic mutations in Pakistani population with late-stage Colorectal cancer (CRC). Methods: This was a descriptive analysis of CRC patients who got their next-generation sequencing (NGS) tests (targeted panel) done at AKUH, Karachi between January 2021 and December 2021. Pathogenic variants were identified using American College of Medical Genetics and Genomics (ACMG) classification. Results: Among the 35 CRC patients analyzed, 31.4% were < 50 years old and 60% were males. Mutation analysis showed a high prevalence of TP53 mutations in 23 patients (65.7%). KRAS mutations were detected in 19 patients (54.3%) Other mutations included PIK3CA in 3(8.6%), NRAS in 3(8.6%), EGFR in 3(8.6%), and MET in 1(2.9%). Double gene mutation (KRAS and TP53) were observed in 13 (37.1%) and (PIK3CA and KRAS) in 2 (5.71%) samples. A triple gene mutations (KRAS, TP53, and PIK3CA) were found in 1 (3%) of CRC tumors. The remaining samples were wild type for genes analyzed. Microsatellite instability (MSI) status was assessed, revealing 2.9% MSI-high tumors, 37.1% MSI-stable tumors, and a concerningly high proportion (60.0%) of samples where MSI testing was not performed. Conclusion: This study highlights distinct a genetic profile of CRC in the Pakistani population, characterized by a significant prevalence of TP53 and KRAS mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.